Share This Link

Cardiotoxicity is not a common adverse effect of cyclophosphamide, an alkylating agent that crosslinks DNA strands and prevents cell division. Cyclophosphamide is used to treat ovarian cancer, a type of cancer that affects the female reproductive organs. Cardiotoxicity may be caused by other drugs, such as anthracyclines and trastuzumab, which are used to treat other types of cancer.

Nephrotoxicity is not a common adverse effect of cyclophosphamide, an alkylating agent that is used to treat ovarian cancer. Nephrotoxicity may be caused by other drugs, such as cisplatin and methotrexate, which are used to treat other types of cancer.

Neurotoxicity is not a common adverse effect of cyclophosphamide, an alkylating agent that is used to treat ovarian cancer. Neurotoxicity may be caused by other drugs, such as vincristine and paclitaxel, which are used to treat other types of cancer.

The liver is not the organ that is protected by amifostine, a chemoprotective agent, from nephrotoxicity caused by cisplatin, a platinum compound that crosslinks DNA strands and prevents cell division. Cisplatin is used to treat lung cancer, a type of cancer that affects the respiratory system. The liver is not the primary target of cisplatin's toxicity, although it can cause hepatotoxicity in some cases. Amifostine does not prevent hepatotoxicity caused by cisplatin.

The heart is not the organ that is protected by amifostine, a chemoprotective agent, from nephrotoxicity caused by cisplatin, a platinum compound that is used to treat lung cancer. The heart is not the primary target of cisplatin's toxicity, although it can cause cardiotoxicity in some cases. Amifostine does not prevent cardiotoxicity caused by cisplatin.

The lungs are not the organ that is protected by amifostine, a chemoprotective agent, from nephrotoxicity caused by cisplatin, a platinum compound that is used to treat lung cancer. The lungs are the primary site of action of cisplatin, as it kills the lung cancer cells. Amifostine does not protect the lung cancer cells from cisplatin's cytotoxic effect, as it does not reach them in its active form. Amifostine does not prevent pulmonary toxicity caused by cisplatin.

Increasing the amount of iron in your blood is not the mechanism of action of epoetin alfa, a bone marrow stimulant that is used to treat anemia caused by chemotherapy. Iron is a mineral that is essential for the synthesis of hemoglobin, a protein that binds oxygen in the red blood cells. Iron deficiency can cause anemia, but it is not the main cause of anemia in clients receiving chemotherapy. Epoetin alfa does not increase the amount of iron in the blood, but it may increase the demand for iron, as more red blood cells are produced. The client may need to take iron supplements along with epoetin alfa to prevent iron deficiency.

Increasing the amount of oxygen in your blood is not the mechanism of action of epoetin alfa, a bone marrow stimulant that is used to treat anemia caused by chemotherapy. Oxygen is a gas that is inhaled from the air and diffuses into the blood through the lungs. The amount of oxygen in the blood depends on several factors, such as the atmospheric pressure, the respiratory rate, and the ventilationperfusion ratio. Epoetin alfa does not increase the amount of oxygen in the blood directly, but it can increase the oxygencarrying capacity of the blood indirectly, by increasing the number of red blood cells.

Increasing the number of platelets in your blood is not the mechanism of action of epoetin alfa, a bone marrow stimulant that is used to treat anemia caused by chemotherapy. Platelets are cell fragments that are involved in blood clotting and hemostasis. Thrombocytopenia is a condition that causes low platelet count and increases the risk of bleeding. Thrombocytopenia can be caused by chemotherapy, but it is not treated by epoetin alfa. Epoetin alfa does not increase the number of platelets in the blood, but it may increase the risk of thrombosis, as more red blood cells can make the blood more viscous. The client may need to take anticoagulant drugs along with epoetin alfa to prevent thrombosis.

Hypertension and headache are not common adverse effects of filgrastim, a bone marrow stimulant that is used to treat neutropenia caused by chemotherapy. Filgrastim is a synthetic form of granulocyte colonystimulating factor (GCSF), a hormone that stimulates the production of neutrophils, a type of white blood cell that fights infection, in the bone marrow. Hypertension and headache may be caused by other factors, such as stress, pain, or dehydration.

Diarrhea and abdominal pain are not common adverse effects of filgrastim, a bone marrow stimulant that is used to treat neutropenia caused by chemotherapy. Diarrhea and abdominal pain may be caused by other drugs, such as antibiotics or antineoplastic agents, that affect the gastrointestinal tract.

Bleeding and bruising are not common adverse effects of filgrastim, a bone marrow stimulant that is used to treat neutropenia caused by chemotherapy. Bleeding and bruising may be caused by thrombocytopenia, a condition that causes low platelet count and increases the risk of bleeding. Thrombocytopenia can be caused by chemotherapy, but it is not treated by filgrastim. Filgrastim does not increase the number of platelets in the blood, but it may increase the risk of splenic rupture, as more white blood cells can enlarge the spleen. The client should have their platelet count and spleen size monitored regularly and report any signs of bleeding or abdominal pain.